Leqvio FDA Approval
50 years of evidence demonstrate that effective and sustained
LDL-C reduction improves cardiovascular outcomes*1,2
Log-linear association per unit change in
LDL-C and the risk of cardiovascular disease5
Proportional Reduction in Risk of CHD (%)
70
50
60
siRNA e.g. LeqvioⓇ
50
mAbs
40
Statins
30
20
10
0
0
Meta-analyses of Mendelian
randomization studies (N=194,427)
Median follow-up 52 years
10
20
30
40
Meta-analyses of Randomized
controlled trials (N=196,552)
Median follow-up 5 years
50
60
70
Each mmol/L reduction in LDL-C
reduces the relative risk of ASCVD events by 20%
after 3 years and 1.5% in each subsequent year³
Relationship between LDL-C and MACE
is supported by clinical trials involving ~500k patients³,4
Relation between LDL-C and outcomes
is well established
Long-term exposure to lower LDL-C (mg/dL)
LDL-C - Low Density Lipoprotein Cholesterol
ASCVD Atherosclerotic Cardiovascular Disease
2. CTT
MACE Major Adverse Cardiovascular Events CV Cardiovascular 1. Silverman MG, et al. JAMA. 2016;316(12):1289-1297.
Collaboration. Lancet 2015;385:1397-1405. 3. Cholesterol Treatment Trialists' (CTT) Collaboration, et al. Lancet. 2010;376(9753):1670-1681. 4. Wang N, et al. Lancet Diabetes Endocrinol. 2020;8:36-49. 5. Figure adapted from Brandts J,
et al. Circulation. 2020;141(11):873-876; Cholesterol Treatment Trialists(CTT) Collaboration European Heart Journal (2018) 39, 2540-2545 -doi:10.1093/eurheartj/ehx450. *Note: The effect of LeqvioⓇ on cardiovascular morbidity and
mortality is currently being studied in the ongoing Phase III ORION-4 and VICTORION-2P trials.
10 Leqvio® FDA Approval | December 23, 2021 | Novartis Investor Presentation
NOVARTIS | Reimagining MedicineView entire presentation